K Koelblinger

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
330 Background: Neoadjuvant chemotherapy (nCT) for pancreatic cancer is increasing due to the fact that 75% of patients diagnosed with pancreatic cancer are borderline or non-resectable. The use of antibodies may improve the efficacy of nCT. The influence on quality of life is not clear. METHODS We prospectively evaluated quality of life in patients(More)
  • 1